When

Saturday, October 26, 2024

6:15 AM-7:15 AM ET

WheRE

Boston, MA

Sheraton Boston Hotel
Constitution B (2nd Floor)
39 Dalton Street
Boston, MA 02199

faculty
John M. Fahrenholz, MD
Assistant Professor of Medicine
Division of Allergy, Pulmonary, and Critical Care Medicine
Department of Medicine
Vanderbilt University Medical Center
Nashville, Tennessee
Lauren M. Madigan, MD
Assistant Professor of Dermatology
University of Utah
Practicing Clinician
University Medical Center and Huntsman Cancer Institute
Salt Lake City, Utah
Anton Rets, MD
Associate Professor of Pathology
University of Utah School of Medicine
Associate Director, Pathology Residency Program
Medical Director, Hematopathology and Immunohistochemistry Laboratory
ARUP Laboratories, Inc.
Salt Lake City, Utah

Breakfast will be provided.

The Non-CME Corporate Forum content and views expressed therein do not necessarily reflect the views, policies or position of the American College of Allergy, Asthma & Immunology.

There is no registration fee for attending this Non-CME Corporate Forum; however, seating is limited. Preregistration does not guarantee seating. We recommend arriving at the meeting room early.

Prefer to participate online? Register for our live stream at ExchangeCME.com/SMBostonLivestream.

Target Audience

The design of this activity addresses the needs of clinical immunologists, allergists, dermatologists, and other attendees of ACAAI who manage patients with nonadvanced systemic mastocytosis (SM).

Program Overview

Nonadvanced systemic mastocytosis (SM) is a difficult disorder to diagnose and manage due to the wide variety of symptoms, anaphylactic triggers, and a complicated individualized treatment paradigm. Join us for this engaging Expert Roundtable™ to hear multidisciplinary insights related to the diagnosis and treatment strategies for nonadvanced SM.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Describe the pathophysiology of nonadvanced SM, including the effects of driver mutations on MC activation and the rationale for new targeted therapies
  • Assess symptoms and analyze laboratory and genetic testing results to differentially diagnose nonadvanced SM and classify subtype
  • Discuss recent clinical trial evidence and regulatory status for new and emerging targeted treatment options, including selective tyrosine kinase inhibitors and their role in treating SM
  • Formulate individualized treatment plans reflecting clinical evidence for treatment efficacy and safety, patient-reported outcomes, and shared decision making

Americans With Disabilities Act

Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact us prior to the live event at info@exchangecme.com.

Fee Information & Refund/Cancellation Policy

There is no fee for this program.

Register Now

attend event
Related events
OCT
25
2024
Medical Jeopardy™
0.00 CME

Non-CME Corporate Forum sponsored by AstraZeneca.

Updates on Chronic Rhinosinusitis With Nasal Polyps: Uncovering Epithelial Targets in the Upper Airways

Time: 8:00 PM-10:00 PM ET
Venue: Live Stream
Location: Live Stream
Faculty: Tanya M. Laidlaw, MD; Joseph K. Han, MD; Flavia Hoyte, MD
OCT
25
2024
Medical Jeopardy™
0.00 CME

Non-CME Corporate Forum sponsored by AstraZeneca.

Updates on Chronic Rhinosinusitis With Nasal Polyps: Uncovering Epithelial Targets in the Upper Airways

Time: 8:00 PM-10:00 PM ET
Venue: Boston Marriott Copley Place Hotel, Grand Ballroom Salon F (4th Floor)
Location: Boston, MA
Faculty: Tanya M. Laidlaw, MD; Joseph K. Han, MD; Flavia Hoyte, MD
OCT
26
2024
Expert Roundtable™ Live Stream
0.00 CME

Non-CME Corporate Forum sponsored by Blueprint Medicines.

Managing Nonadvanced Systemic Mastocytosis: An Expert Roundtable Session

Time: 6:15 AM-7:15 AM ET
Venue: Live Stream
Location: Live Stream
Faculty: John M. Fahrenholz, MD; Lauren M. Madigan, MD; Anton Rets, MD